FibroBiologics, Inc. Stock-Based Compensation
FibroBiologics, Inc. (FBLG) reported Stock-Based Compensation of $1.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-07-31
- FibroBiologics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $707.00K, a 3.02% decline year-over-year.
- FibroBiologics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $694.00K, a 25.95% increase year-over-year.
- FibroBiologics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $702.00K, a 29.04% increase year-over-year.
- FibroBiologics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $704.00K, a 23.08% increase year-over-year.
- FibroBiologics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $2.69M, a 21.05% increase from fiscal 2024.
- FibroBiologics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $2.22M, a 25.72% increase from fiscal 2023.
- FibroBiologics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.76M, a 566.04% increase from fiscal 2022.
- FibroBiologics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $265.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $707.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $1.40M 10-Q · filed 2026-07-31 | $2.10M derived: sum of 3 quarters · filed 2026-07-31 | $2.81M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $694.00K 10-Q · filed 2026-04-30 | $1.40M derived: sum of 2 quarters · filed 2026-04-30 | $2.10M derived: sum of 3 quarters · filed 2026-04-30 | $2.83M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $702.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.41M derived: sum of 2 quarters · filed 2026-02-24 | $2.13M derived: sum of 3 quarters · filed 2026-07-31 | $2.69M 10-K · filed 2026-02-24 |
| 2025-09-30 | $704.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-31 | $1.43M derived: sum of 2 quarters · filed 2026-07-31 | $1.98M 10-Q · filed 2025-10-31 | $2.53M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $729.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $1.28M 10-Q · filed 2026-07-31 | $1.82M derived: sum of 3 quarters · filed 2026-07-31 | $2.40M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $551.00K 10-Q · filed 2026-04-30 | $1.09M derived: sum of 2 quarters · filed 2026-04-30 | $1.67M derived: sum of 3 quarters · filed 2026-04-30 | $2.25M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.12M derived: sum of 2 quarters · filed 2026-02-24 | $1.69M derived: sum of 3 quarters · filed 2026-02-24 | $2.22M 10-K · filed 2026-02-24 |
| 2024-09-30 | $572.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-31 | $1.15M derived: sum of 2 quarters · filed 2025-10-31 | $1.68M 10-Q · filed 2025-10-31 | $2.11M derived: sum of 4 quarters · filed 2025-10-31 |
| 2024-06-30 | $578.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $1.10M 10-Q · filed 2025-07-31 | $1.53M derived: sum of 3 quarters · filed 2025-07-31 | $1.97M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $525.00K 10-Q · filed 2025-05-14 | $957.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.39M derived: sum of 3 quarters · filed 2025-05-14 | $1.84M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $432.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $869.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.32M derived: sum of 3 quarters · filed 2025-03-31 | $1.76M 10-K · filed 2025-03-31 |
| 2023-09-30 | $437.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $885.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.33M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $448.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $896.00K 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $448.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $265.00K 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |